MECOM and myelodysplastic syndrome: They concluded that the conventional classification of patients with myeloid neoplasms carrying MECOM rearrangements into MDS or AML, based on a threshold of 20% bone marrow blasts, does not accurately reflect genetic profiles or clinical outcomes.